Influenza Vaccine in Final Bulk
As a well-known, trustworthy and listed biotechnology
company in China, Changchun BCHT Biotechnology Co. ([BCHT")
has dedicated to biotechnology for over a decade and grown by leaps and bumps.
And we hereby proudly introduce our products as below:
Influenza Vaccine, Live, Nasal,
Freeze-dried (exclusively authorized by the WHO in China, for 3-17 years
old, no injection and no pain)
The vaccine is inoculated by nasal spray,
equipped with nasal spray device, and only needs to spray once a year in two
nostrils to prevent influenza.
Mucosal immunity + Cellular immunity +
Humoral immunity
Vaccination of Influenza Vaccine, Live, Nasal, Freeze-dried can quickly stimulate the triple immune response of human body, and carry out defense against viruses in different parts:
·Intranasal administration can produce mucosal immunity (IgA antibody), which forms the first immune defense line in the nasal cavity.
·Produce humoral immunity (IgG antibody) to remove influenza virus from body fluids.
·Produce cellular immunity (T cells) to remove influenza virus from cells
Changchun BCHT Biotechnology Co.`s Influenza Vaccines can also be manufactured in final bulk form.
Look forward to your early reply.
Changchun BCHT Biotechnology Co. , https://www.ccbcht.net
Academic promotion returns to the nature of the product
Otsuka Pharmaceutical uses a product feature based on a large number of high-level research evidence that “Peda, the risk of bleeding is less and it is more suitable for Asians' anti-platelet drugs†matches the doctor’s “question for bleeding risk in stroke secondary preventionâ€. The clinical needs of lower and safer drugs have provided patients with safer treatment options and enabled Peida to successfully enter the new indication market.
When we are patient-centered, we carefully study product characteristics and use product characteristics to match clinical needs, provide clinicians with the most reasonable treatment options, provide patients with safer, more effective treatment options, and ultimately allow patients to benefit, academic promotion will be Become more effective, become the driving force of drug marketing, and is no longer just in the form of a meeting.
China has always been the fastest growing region in the global pharmaceutical market. Annual sales of trillions of dollars and annual growth rates of more than 20% have caused many pharmaceutical companies to resort to a piece of glass. After the GSK incident, the government departments successively issued a number of policies that show that the supervision of anti-commercial bribery in the pharmaceutical industry will continue to remain high and the unspoken rules of the industry will gradually be broken. Academic promotion has become one of the most important models.
The two most important elements of academic promotion are the product characteristics based on a large number of high-level research evidence and the clinical treatment needs that match the indication. The author will use Peida (cilostazol tablets) as an example of the indications of peripheral arterial disease and enter the secondary prevention market for ischemic stroke as an example to analyze how product characteristics match clinical needs.
Cilostazol was synthesized by Japan Otsuka Pharmaceutical Co., Ltd. in 1978. It was marketed in Japan under the trade name Pletaal in 1988, listed in China in 1997, listed in the United States in 1999, and listed in the European Union in 2000. This product has been used as a preferred drug for the treatment of peripheral arterial disease by inhibiting phosphodiesterase activity in platelets and vascular smooth muscle, increasing platelet and smooth muscle cAMP concentrations, and exerting antiplatelet and vasodilator effects.
However, as an anti-platelet drug, ischemic stroke prevention will be a bigger market. Moreover, aspirin and clopidogrel, the most commonly used drugs for ischemic stroke prevention, can cause drug resistance over a long period of time and have a risk of bleeding. Facing this market opportunity, Otsuka Pharmaceutical has done a lot of research work.
High-level research evidence
Compared to other antiplatelet agents, cilostazol has many additional targets that not only prevent platelet aggregation but also act on other factors related to thrombosis, including improving endothelial cell function, by increasing NO production and decreasing Intracellular calcium concentration can dilate blood vessels, and it can also inhibit smooth muscle hyperplasia and inflammation in different vascular beds.
The product's unique anti-platelet effect, protection of vascular endothelium, and dilation of blood vessels make it possible to reduce bleeding risk while exerting anti-platelet effects. It is used for secondary prevention of ischemic stroke and is theoretically superior to traditional anti-platelet therapy. The drug is more effective and safe, and a large number of animal experiments have also confirmed this view.
In 2000, Professor Kazuo Kazuo, professor of neurology at Keio University in Japan, published a cilostazol prevention stroke study (CSPS) in Japan in the Journal of Stroke and Cerebrovascular Disease: cilostazol compared with placebo. Significantly reduce the recurrence rate of ischemic stroke without increasing the incidence of cerebral hemorrhage.
Takeo Kazuo is the winner of the 1995 Thomas Willis Prize (the highest award in global stroke research) and was the chairman of the International Stroke Association (ISS). By such an academic authority, it took 2 years to cross over 183 clinical research institutes in Japan and tracked 1052 patients. The conclusion that cilostazol is safe and effective in preventing ischemic stroke was achieved. The secondary prevention market for stroke laid the theoretical foundation.
However, the market for stroke secondary prevention was long occupied by aspirin. In 1998, the listing of Plavix (clopidogrel) further exacerbated market competition. How to open up a new world of Peida in the situation where Aspirin and Polivi dominated? Otsuka Pharmaceutical has started a new journey.
Matching clinical needs
In the secondary prevention program of ischemic stroke, the risk of bleeding caused by the long-term use of antiplatelet drugs has attracted attention. There have been several studies that have attempted to combine different mechanisms of anti-platelet drugs to reduce the risk of bleeding but have failed.
A number of domestic and international clinical studies have found that after long-term use of antiplatelet drugs in Asian populations, the risk of bleeding is significantly higher than that of other ethnic groups. Even studies have shown that using the same treatment plan for secondary prevention of ischemic stroke, the incidence of cerebral hemorrhage and other hemorrhagic events in Chinese patients is higher than in Western countries, and the prognosis is even worse. The search for drugs with lower risk of bleeding and more safety has become a new need for clinical treatment.
Otsuka Pharmaceutical's Market Medicine Department reviewed Peda's pharmacological mechanisms, preclinical tests, and clinical data before and after the listing. Pharmacology, animal experiments, and clinical data all confirmed that Peida's bleeding risk was lower than that of aspirin and Plavix.
In 2008, Prof. Huang Yining of the First Hospital of Peking University and others published a comparative study of the effect of cilostazol versus aspirin after ischaemic stroke published in the Lancet (CASISP): Overall, the cilostazol group The incidence of ischemic and hemorrhagic stroke is lower, and the incidence of cerebral hemorrhage complications is significantly lower than that of the aspirin group. It is safe and may be more appropriate for patients with secondary ischemic stroke who have a higher risk of bleeding.
This study suggests that cilostazol is safer than aspirin in the prevention of ischemic stroke. In the same year, the original SFDA approved cilostazol to increase the new indication "prevention of recurrent ischemic stroke (excluding cardiogenic ischemic stroke)", which has played a decisive role in Peda's entry into the secondary prevention market for stroke.
In 2010, Professor Shikio Kasahara of Tokyo Tachikawa Hospital in Japan issued the results of the study on the prevention of secondary stroke (CSPS2) in the Lancet. Compared with aspirin, cilostazol can reduce the risk of stroke. The effect was better, and the incidence of bleeding episodes in the cilostazol group was significantly reduced. Only adverse reactions such as headache and diarrhea were more common. This study confirmed the results of the CASISP study. In the subsequent International Conference on Neurology, Dr. Shinohara's CSPS2 research findings have caused widespread repercussions, and neurophysiologists have begun to pay attention to this drug.
Based on the above high-level clinical evidence, cilostazol has occupied a place in secondary prevention of ischemic stroke. The American College of Chest Physicians (ACCP) Guide to Antithrombotic Therapy (CHEST 2012), Chinese Guidelines for the Prevention and Treatment of Cerebral Vascular Diseases (2010), and the Japanese Guidelines for Stroke Treatment (2009) have all included The azole is one of the recommended drugs for secondary prevention of ischemic stroke.